Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | ABL1 | P00519 | 3/20 | 0.68 |
| ▸ | RIN1 | Q13671 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11145933 | 0.83 | TDP1 (0.72) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL721824 | 0.80 | TDP1 (0.60) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL18106287 | 0.79 | TDP1 (0.58) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL18106267 | 0.79 | TDP1 (0.58) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL924239 | 0.79 | TDP1 (0.58) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL723098 | 0.79 | TDP1 (0.57) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL723615 | 0.77 | TDP1 (0.59) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL18106239 | 0.76 | TDP1 (0.64) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL18106226 | 0.76 | TDP1 (0.64) | TDP1ABL1RIN1KDM4EKMT2A | |
| SCHEMBL18106282 | 0.76 | TDP1 (0.64) | TDP1ABL1RIN1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296952-A | Anti-reflective coatings | AZ ELECTRONIC MATERIALS USA (US) | 2008-10-29 | — | — | CN | claimed |
| EP-1966255-A1 | ANTI-REFLECTIVE COATINGS | AZ Electronic Materials USA Corp. (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007052132-A1 | ANTI-REFLECTIVE COATINGS | AZ ELECTRONIC MATERIALS USA CORP. (DE) | 2007-05-10 | — | — | WO | claimed |
| US-20070099108-A1 | Anti-reflective coatings | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| EP-1608691-B1 | CROSSLINKING COMPOSITION | ALLNEX IP SARL (LU) | 2018-04-11 | — | — | EP | disclosed |
| CN-107428781-A | Mercaptoethyl glycoluril compounds and its application | 四国化成工业株式会社 | 2017-12-01 | — | — | CN | disclosed |
| EP-1794202-B1 | STABILIZED CROSSLINKING COMPOSITION | CYTEC TECH CORP (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8043526-B2 | Stabilized crosslinking composition | CYTEC TECHNOLOGY CORP. (US) | 2011-10-25 | — | — | US | disclosed |
| CN-101061152-B | Stabilized crosslinking composition | CYTEC TEC CORP | 2011-03-09 | — | — | CN | disclosed |
| CN-100503674-C | Crosslinked composition | CYTEC TECH CORP (US) | 2009-06-24 | — | — | CN | disclosed |
| US-20090043072-A1 | Stabilized crosslinking composition | ALLNEX NETHERLANDS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| US-7442325-B2 | Stabilized crosslinking composition | CYTEC TECHNOLOGY CORP. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1794202-A1 | STABILIZED CROSSLINKING COMPOSITION | CYTEC SURFACE SPECIALTIES, S.A. (BE) | 2007-06-13 | — | — | EP | disclosed |
| CN-1768087-A | Crosslinking composition | CYTEC TECH CORP (US) | 2006-05-03 | — | — | CN | disclosed |
| WO-2006039030-A1 | STABILIZED CROSSLINKING COMPOSITION | CYTEC TECHNOLOGY CORP. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074203-A1 | producing the crosslinking composition by reacting an amino compound; a mono(alkylaldehyde) and/or a poly(alkylaldehyde), and an alcohol; and adding an organic compound; stabilized aminoplast-based crosslinking compositions | ALLNEX NETHERLANDS B.V. (NL) | 2006-04-06 | — | — | US | disclosed |
| EP-1608691-A1 | CROSSLINKING COMPOSITION | CYTEC TECHNOLOGY CORP. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004094497-A1 | CROSSLINKING COMPOSITION | CYTEC TECHNOLOGY CORP. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040192851-A1 | Crosslinking composition | ALLNEX NETHERLANDS B.V. (NL) | 2004-09-30 | — | — | US | disclosed |
| US-4009134-A | RESORCINOL-FORMALDEHYDE RESIN | THE GENERAL TIRE & RUBBER COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192851-A1 | Crosslinking composition | ADH1C, ADH1A, CBR1 | TDP1 1937/4885ABL1 1101/4885RIN1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.